AVXL - Earnings call transcript Q4 2024 | Anavex Life Sciences Corp.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Clint Tomlinson

Good morning, and welcome to the Anavex Life Sciences Fiscal 2024 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. [Operator Instructions] Please note that this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Chief and and Financial Boenisch, President Officer. Missling, Executive Sandra Officer; Principal Christopher

results which to please this uncertainties. or these These that company we number may the information note Before company's begin, involve limitation, and during predictions review includes, on This without some that a and and expectations materially only risks will differ projections conference the encourage forward-looking you are to statements. forward-looking factors XX-K, and events company's statements of based identify current We XX-Q, make the from SEC. cause in specific filings actual with the described the Forms those statements. call,

in approvals, and maintenance These to limitation, development inherent factors capital our the need obtain include, clinical future property intellectual in risks without trials or results and the of products, ability regulatory commercialization rights. may uncertainty of and of potential

over And the like to I'd turn call Missling. to with Dr. that,

Christopher Missling

Happy Merry and Clint, you with you, Thank review update. to us to everybody. reported results provide today business happy our for and and good very quarterly our Thank being financial to everyone, and soon, and recently holidays most Christmas, New morning, Year,

advance by and meaningfully precision to continue important program, developments. highlighted differentiated We clinical several medicine our announcements recent

early up Phase study XXX-week is entitled MAA Alzheimer's ANAVEX-XXX this open-label filed The has for we the month. was data in of In accepted Alzheimer's treatment authorization it's the investigating submission double-blind last disease, by to European MAA, EMA, the by blarcamesine blarcamesine for disease. ATTENTION-AD, IIb/III morning, Anavex from randomized disease, trial, and for supported announced marketing Medicines Agency, that application, review placebo-controlled extension the Alzheimer's which

in filing a a a to broader for us people patient to blarcamesine estimated review EMA new Alzheimer's with access forward MAA option by according European the and step to with The Brain to number we continued an offering Europe, look closer X XXXX in brings Europe are treatment the engagement to potentially There acceptance expected Council. double EMA. million disease, to

upcoming ATTENTION-AD at of place line Healthcare San its recently, XX, the Conference, presentation top extension data trial announced to XX California. from in long-term Also XXXX January Anavex Francisco, the JPMorgan taking XXXX open-label

a for of Anavex quarter. disease Phase titled expected reported II/III disease. the the from manuscript in journal on peer-reviewed the treatment the the blarcamesine results The upcoming early with is acceptance Alzheimer's In of or current trial publication Alzheimer's a medical either within focus November, ANAVEXX-XX-AD-XXX

through new the prespecified Finally, IIb/III at demonstrates the presented of end activation. gene SIGMARX daily Clinical action data the study confirmed orally, we clinical October, upstream efficacy Phase data from a blarcamesine analysis SIGMARX once of showing prespecified by at The Barrow at Alzheimer's Marwan in CTAD clinical Board Alzheimer's people the Neurological Sabbagh, Disease data Anavex early the of Scientific with Professor presented Advisory Institute Spain. on disease. trials by in conference of Madrid, Chairman and were Neurology mechanism

EEG of key ANAVEX results the in Preliminary ANAVEX respect duration treatment placebo-controlled also EEG dose-dependent a October, encouraging with A expect the Part II of Anavex schizophrenia. With Phase announced treatment from data electroencephalo X X-XX, half the X-XX in biomarkers on X-XX in first ongoing in longer B the which results demonstrated from ANAVEX to study, of Part Phase study for schizophrenia. of of effect of participants more II XXXX. patients includes a placebo-controlled Anavex clinical preliminary biomarker

And of Anavex, of Financial Sandra summary Boenisch, now the financial quarter. for Officer call Principal would to like recently a reported direct I the to

Sandra Boenisch

year. Christmas I'm Merry good to everybody you, the morning to well. fourth quarter with as results Thank you share for our pleased fiscal Christopher, today and financial and XXXX

no $XXX.X was position million, at debt. and had cash we . Our XX September

of in noncash fiscal we million year-end, operating into approximately And as in $X.X and activities runway years. cash a at account capital quarter, after of During taking anticipate utilized utilization X equivalents of we the changes current the accounts. cash rate, cash working

were compared administrative recent During quarter. and million $X.X most third as general to $X.X the quarter, our expenses immediately million preceding in

quarter million quarter. expenses And as Our $XX.X for per $XX.X compared for preceding research reported loss to third million $XX.X the immediately were quarter the the lastly, net million a for share. or and $X.XX development of we

Thank you. you, back And to now Christopher.

Christopher Missling

a alongside from strides presenting team executing the has Thank and advance to treatment momentum. oral I'm early of on Alzheimer's made are of our potentially disease you, treatment committed individuals we with the Sandra. team the convenient for making quarter Alzheimer's ease Anavex alternative excited the the recent for In remains in about suffering dosing, proud very scalable disease by to difference summary, administration. a potential novel deeply oral a to our

I would call Q&A the to . for to back Clint now turn like

Clint Tomlinson

Christopher, is you [Operator you some Tom, share came Instructions] that. from can I question if can't Christopher, with coming is from the see It you know out to make question, don't be trouble Tom I with that joining. that the seems I here, don't first can And Bishop. this on. There question is see Tom -- one I Tom

Christopher Missling

cannot. I

Clint Tomlinson

Okay.

-- make of a based EMA think question the is it's decision. to I the along timing the

Christopher Missling

is from guess. we this days and a XXX what review going process, the So standardized expect. I now And is that process. yes, which is that's forward,

Clint Tomlinson

Okay.

status have that this? has any Another of remarkable or question on Is is that there the shown some patients update Australian improvement. Tom

Christopher Missling

top on the So update data open-label conference. extension JPMorgan we study, ATTENTION-AD, as expect line during we said,

an update So then. have by will we

Clint Tomlinson

any this coming other questions At don't point, I Okay. in. see

that you, any back So comments. like turn other for I Christopher, to over would to

Christopher Missling

well much. Christmas. lives, we on closing, Merry at and these pipeline the Thank you of Christmas, New commercial living And with happy to execution readiness very thank and you conditions. as advance you And very Thank to again, to again, focus us as Happy devastating much. improve therapeutic our in potentially patients' we and everybody. continue joining for holidays And Year today eve

Clint Tomlinson

And call. please Again, with that, that closes holidays. your the enjoy

Anavex Life Sciences (AVXL) 23 Dec 242024 Q4 Earnings call transcript